Classical Hodgkin Lymphoma - Pathology and Biology
Dr. Hsi will review the pathologic features of classic Hodgkin lymphoma, discuss differential diagnostic considerations, and review recent advances in our understanding of the biology of Hodgkin lymphoma with an emphasis on molecular genetic and micrcoenvironmental features.
Below is a list of questions received from the live webinar attendees. Click on any question to reveal the speaker's response.NEW QUESTION/ANSWER
It is common to see necrosis in cHL, hard to put a number on it offhand.
Classic in the 2017 WHO
It can be expressed in both CHL and ALCL so it may not be reliable.
CD15, CD30, CD20, PAX5, OCT2, BOB1 and CD45 can be helpful.
I have never seen this.
No, there is no clinical role for this at present.
This would be highly unusual
I don’t have any experience with J chain but is usually negative in RS-cells. MUM1 is typically positive but not specific.
Yes. J-chain and MEF2B have been reported to be useful as well. PMID: 28851661
I don’t think it is particularly helpful, some cases of cHL may have rearranged IGH
I don’t find it that helpful
There has been some data to suggest it is prognostic.
It does not appear to commonly result in loss of CD30 expression in follow-up biopsy but I don’t believe this has been extensively studied.
Yes, for T-cell lymphomas including cutaneous T-cell lymphomas it is reasonable to report the % positive tumor cells because some trials that resulted in the approval of brentuximab used specific cutoffs.